Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A new paradigm for HIV-1 treatment

AIDS Reviews

Volumn 16, Issue 1, 2014, Pages 35-42

  Manzardo, Christian ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cobicistat; Elvitegravir; HAART; HIV 1; Naive patients; Single tablet treatment; Treatment experienced patients

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; DEOXYCYTIDINE; DRUG COMBINATION; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; QUINOLONE DERIVATIVE; TENOFOVIR DISOPROXIL; THIAZOLE DERIVATIVE;

ADVERSE OUTCOME; ANTIVIRAL ACTIVITY; ASTHENIA; CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIA; NAUSEA; RASH; REVIEW; ANALOGS AND DERIVATIVES; DRUG COMBINATION; HIV INFECTIONS; UNITED STATES;

ADENINE; ANTI-HIV AGENTS; CARBAMATES; DEOXYCYTIDINE; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; QUINOLONES; THIAZOLES; UNITED STATES;

EID: 84896808364     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv- guidelines/0. [Accessed 12 January, 2014].
2. Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2014;30:89-97.
3. Llibre J, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14:168-78.
4. Perry C. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults. Drugs. 2013;74:75-97.
5. Permpalung N, Putcharoen O, Avihingsanon A, Ruxrungtham K. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother. 2012;13:2301-17.
6. Eron J, Rockstroh J, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11:907-15.
7. Taltynov O, Desimmie B, Demeulemeester J, Christ F, Debyser Z. Cellular cofactors of lentiviral integrase: from target validation to drug discovery. Mol Biol Int. 2012;2012:863405.
8. Hicks C, Gulick R. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48:931-9.
9. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5. (Pubitemid 44306480)
10. Messiaen P, Wensing A, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One. 2013;8:e52562.
11. Deeks E. Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection. Drugs. 2013. [E-pub ahead of print].
12. Gilead Sciences Inc. US prescribing information for Stribild®; 2013. Available at: http://www.gilead.com/*/media/Files/pdfs/medicines/hiv/ stribild/stribild-pi.pdf [Accessed 11 January, 2014].
13. European Medicines Agency. Stribild 150 mg/150 mg/200 mg/ 245 mg film-coated tablets: Summary of product characteristics; 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002574/WC500144272.pdf [Accessed 12 January, 2014].
14. Menéndez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in HIV type 2 infection. Antiviral Res. 2013;102C:70-86.
15. Menéndez-Arias L. Molecular basis of HIV type 1 drug resistance: overview and recent developments. Antiviral Res. 2013;98:93-120.
16. Hurt C, Sebastian J, Hicks C, Eron J. Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009-2012. Clin Infect Dis. 2014;58:423-31.
17. Ramanathan S, Mathias A, German P, Kearney B. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50:229-44.
18. German P, Warren D, West S, Hui J, Kearney B. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55:323-9.
19. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25:F7-12.
20. Sax P, De Jesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439-48.
21. De Jesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429-38.
22. Zolopa A, Sax P, De Jesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate versus efavirenz/emtricitabine/ tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63:96-100.
23. Rockstroh J, De Jesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/ tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62:483-6.
24. Clumeck N, Molina J-M, Henry K, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/ emtricitabine/tenofovir DF versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013. [Epub ahead of print].
25. Wohl D, Cohen C, Gallant J, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/ emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013. [Epub ahead of print]
26. Lepist E-I, Phan T, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56:5409-13.
27. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32-40.
28. Sax P, Tierney C, Collier A, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-201.
29. Molina J-M, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012;12:27-35.
30. Imaz A, del Saz S, Ribas M, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52:382-6.
31. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49:1441-9.
32. Elion R, Molina J-M, Arribas J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr. 2013;63:494-7.
33. Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients. Available at: http://clinicaltrials.gov/ct2/show/record/NCT01495702?term= elvitegravir+switch&rank=3. [Accessed 10 January, 2014].
34. Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients. Available at: http://clinicaltrials.gov/ct2/show/NCT01475838? term=elvitegravir+switch&rank=4. [Accessed 10 January, 2014].
35. Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients. Available at: http://clinicaltrials.gov/ct2/show/NCT01533259?term=elvitegravir+switch& rank=5. [Accessed 10 January, 2014].
36. Parienti J-J, Bangsberg D, Verdon R, Gardner E. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484-8.
37. Sax P, Meyers J, Mugavero M, Davis K. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7:e31591.
38. ViiV Healthcare. ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV. Available at: http://www.viivhealthcare.com/media/press- releases/2013/october/viiv-healthcare-announc-es-us-regulatory-submission-for-a- single-tablet-regimen-combining-do-lutegravir-with-abacavir-and-lamivudine-for- people-living-with-hiv.aspx. [Accessed 12 January, 2014].
39. Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. Available at: http://clinicaltrials.gov/ct2/show/ NCT01565850?term= darunavir+single+tablet&rank=2. [Accessed 12 January, 2014].
40. EACS European AIDS Clinical Society. Guidelines. Version 7. Available at: http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf [Accessed 12 January, 2014].
41. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2014)] Avalable at: http://www.gesida-seimc.org/contenidos/guiasclinicas/2014/gesida- guiasclinicas-2014-tar.pdf. [Accessed 6 February, 2014].
42. Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.
43. Juday T, Correll T, Anene A, Broder M, Ortendahl J, Bentley T. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/ teno-fovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. Clinicoecon Outcomes Res. 2013;5:437-45.